Molecular Imaging and Carbonic Anhydrase IX-Targeted Radioimmunotherapy in Clear Cell Renal Cell Carcinoma

Abstract

Conventional imaging is suboptimal at evaluating disease status in renal cell carcinoma (RCC) because of poor sensitivity. Furthermore, there is an unmet need for the treatment of metastatic RCC, both in terms of improvement of progression-free survival and limitation of toxicity. For this reason, radionuclide imaging and radionuclide therapy are extensively investigated. This review provides an overview of the current progress in molecular imaging and radionuclide therapy in clear cell RCC and will focus on promising detection and therapy strategies targeting the carbonic anhydrase IX antigen, which is expressed in clear cell RCC.

KEYWORDS::

• carbonic anhydrase IX
• G250
• girentuximab
• molecular imaging
• renal cell carcinoma

Financial & competing interests disclosure

PA Mulders, W Oyen and O Boerman serve on an advisory board for Wilex AG, Munich, Germany. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.